The US Food and Drug Administration (FDA) approved Koselugo (selumetinib) for the treatment of neurofibromatosis type 1 (NF1) for children ages 2-17 who have plexiform neurofibromas (PN) that cause symptoms and cannot be completely removed by surgery, or for which surgery is not advisable due to potential unwanted side effects with surgery.